ArticleAging clinical and experimental research2025
Letter to the Editor: "Global, regional, and national burden of malignant neoplasm of bone and articular cartilage in adults aged 65 years and older, 1990-2021: a systematic analysis based on the global burden of disease study 2021".
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent publication by Zhang et al. on the burden of malignant neoplasm of bone and articular cartilage in the geriatric population reports age-standardized incidence, prevalence, disability-adjusted life year (DALY), and mortality rates. The authors present age-standardized rates for the 6+ age group based on the Global Burden of Disease (GBD) 2021 study. However, calculating age-standardized measures for a single age group is methodologically inconsistent and may lead to misinterpretation. These measures are designed to compare populations with varying age distributions by applying a uniform age structure. Thus, the GBD 2021 study only offers age-standardized rates for total populations, not specific age groups. Moreover, the 65 + group is not among the predefined age groups in the GBD 2021 study for any health measures. While crude numbers for custom age groups, such as individuals aged 65 years and older, can be derived from the available data, estimating incidence, prevalence, DALY or mortality rates requires complex calculations that cannot be reproduced externally. These limitations raise notable concerns about the reliability of the reported measures and their interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.